The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries-Reference-Cited by-同舟云学术

The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries

Published:2019-07-26 Issue:11 Volume:40 Page:
ISSN:1059-7794
Container-title:Human Mutation
language:en
Short-container-title:Human Mutation

Author:

Laitman Yael¹^ORCID,Friebel Tara M.²^ORCID,Yannoukakos Drakoulis³^ORCID,Fostira Florentia³^ORCID,Konstantopoulou Irene³^ORCID,Figlioli Gisella⁴^ORCID,Bonanni Bernardo⁵^ORCID,Manoukian Siranoush⁶,Zuradelli Monica⁷,Tondini Carlo⁸^ORCID,Pasini Barbara⁹^ORCID,Peterlongo Paolo⁴,Plaseska‐Karanfilska Dijana¹⁰^ORCID,Jakimovska Milena¹⁰^ORCID,Majidzadeh Keivan¹¹^ORCID,Zarinfam Shiva¹¹^ORCID,Loizidou Maria A.¹²^ORCID,Hadjisavvas Andreas¹²^ORCID,Michailidou Kyriaki¹²^ORCID,Kyriacou Kyriacos¹²^ORCID,Behar Doron M.¹³^ORCID,Molho Rinat Bernstein¹⁴¹⁵^ORCID,Ganz Patricia¹⁶^ORCID,James Paul¹⁷^ORCID,Parsons Michael T.¹⁸^ORCID,Sallam Aminah¹⁹^ORCID,Olopade Olufunmilayo I.¹⁹^ORCID,Seth Arun²⁰^ORCID,Chenevix ‐ Trench Georgia¹⁸^ORCID,Leslie Goska²¹^ORCID,McGuffog Lesley²¹^ORCID,Marafie Makia J²²^ORCID,Megarbane Andre²³^ORCID,Al‐Mulla Fahd²⁴^ORCID,Rebbeck Timothy R.²²⁵^ORCID,Friedman Eitan¹¹⁵^ORCID

Affiliation:

1. The Susanne Levy Gertner Oncogenetics Unit The Institute of Human Genetics, Sheba Medical Center Tel‐Hashomer Israel

2. Dana‐Farber Cancer Institute Boston MA

3. Molecular Diagnostics Laboratory, INRASTES National Centre for Scientific Research Demokritos Athens Greece

4. Genome Diagnostics Program IFOM, the FIRC Institute of Molecular Oncology Milan Italy

5. Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS Milan Italy

6. Unit of Medical Genetics, Department of Medical Oncology and Hematology Fondazione IRCCS Istituto Nazionale dei Tumori (INT) Milan Italy

7. Medical Oncology and Hematology Department Humanitas Cancer Center Milan Italy

8. Department of Medical Oncology Ospedale Papa Giovanni XXIII Bergamo Italy

9. Department of Medical Sciences University of Turin Turin Italy

10. Macedonian Academy of Sciences and Arts Research Centre for Genetic Engineering and Biotechnology Skopje Republic of Macedonia

11. Department of Genetics, Breast Cancer Research Center, Motamed Cancer Institute ACECR Tehran Iran

12. Department of Electron Microscopy/Molecular Pathology, The Cyprus Institute of Neurology and Genetics The Cyprus School of Molecular Medicine Nicosia Cyprus

13. Igentify Tirat Hacrmel Israel

14. The Institute of Oncology Sheba Medical Center Tel‐Hashomer Israel

15. The Sackler School of Medicine Tel‐Aviv University Tel‐Aviv Israel

16. Schools of Medicine and Public Health, Division of Cancer Prevention & Control Research Jonsson Comprehensive Cancer Centre, UCLA Los Angeles CA

17. Parkville Familial Cancer Peter MacCallum Cancer Center, Sir Peter MacCallum Department of Oncology The University of Melbourne Melbourne Victoria Australia

18. Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute Queensland Institute of Medical Research Brisbane Australia

19. Center for Clinical Cancer Genetics The University of Chicago Chicago IL

20. Department of Laboratory Medicine and Pathobiology, Faculty of Medicine University of Toronto Canada

21. Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care University of Cambridge Cambridge England

22. Kuwait Medical Genetics Center Maternity Hospital Kuwait

23. Institut Jerome Lejeune Paris France

24. Department of Genetics and Bioinformatics Dasman Diabetes Institute Kuwait City Kuwait

25. Harvard T.H. Chan School of Public Health Boston MA

Publisher

Wiley

Subject

Genetics(clinical),Genetics

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/humu.23842

Reference42 articles.

1. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early‐onset breast cancer patients among Ashkenazi women;Abeliovich D.;American Journal of Human Genetics,1997

2. Predominance of high-grade pathway in breast cancer development of Middle East women

3. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history

4. Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation

5. Lifestyle related risk factors for breast cancer in Jordanian females;Atoum M. F.;Saudi Medical Journal,2004

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing;Pathology - Research and Practice;2024-02

2. Double Heterozygosity for Rare Deleterious Variants in the BRCA1 and BRCA2 Genes in a Hungarian Patient with Breast Cancer;International Journal of Molecular Sciences;2023-10-18

3. Determination of genetic predisposition to early breast cancer in women of Kazakh ethnicity;Oncotarget;2023-10-04

4. RecurrentBRCA2exon 3 deletion in Assyrian families;Journal of Medical Genetics;2023-09-01

5. Burden of breast cancer and attributable risk factors in the North Africa and Middle East region, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019;Frontiers in Oncology;2023-08-01